PSD 506

Drug Profile

PSD 506

Alternative Names: PSD-506

Latest Information Update: 28 May 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Developer Plethora Solutions
  • Class Urologics
  • Mechanism of Action Muscarinic M2 receptor antagonists; Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Neurogenic bladder; Overactive bladder

Most Recent Events

  • 25 Feb 2013 Discontinued - Phase-II for Neurogenic bladder in United Kingdom (PO)
  • 25 Feb 2013 Discontinued - Phase-II for Overactive bladder in United Kingdom (PO)
  • 24 Jan 2011 PSD 506 is still available for licensing as of 24 Jan 2011.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top